COOPER COMPANIES, INC. COO
The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year.
Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and women's health. For financial information relating to these business segments, refer to Note 12. Business Segment Information in Item 8. Financial Statements and Supplementary Data of this Annual Report.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.09B | $3.90B | $3.59B | $3.31B | $2.92B | $2.43B | $2.65B | $2.53B | $2.14B | $1.97B |
| Cost of revenue | $1.41B | $1.30B | $1.24B | $1.17B | $966.7M | $896.1M | $896.6M | $900.5M | $773.2M | $793.7M |
| Gross profit | $2.68B | $2.60B | $2.36B | $2.14B | $1.96B | $1.53B | $1.76B | $1.63B | $1.37B | $1.17B |
| R&D | $172.2M | $155.1M | $137.4M | $110.3M | $92.7M | $93.3M | $86.7M | $84.8M | $69.2M | $65.4M |
| SG&A | $1.63B | $1.53B | $1.50B | $1.34B | $1.21B | $992.5M | $996.2M | $973.3M | $799.1M | $722.8M |
| Operating income | $682.9M | $705.7M | $533.1M | $507.6M | $505.8M | $311.8M | $546.7M | $403.1M | $429.1M | $324.1M |
| Interest expense | $100.0M | $114.3M | $105.3M | $57.3M | $23.1M | $36.8M | $68.0M | $82.7M | $33.4M | $26.2M |
| Pre-tax income | $566.5M | $582.3M | $412.9M | $475.3M | $491.5M | $266.5M | $477.4M | $331.9M | $394.0M | $295.6M |
| Income tax | $191.6M | $190.0M | $118.7M | $89.5M | $2.45B | $28.1M | $10.7M | $192.0M | $21.1M | $20.7M |
| Net income | $374.9M | $392.3M | $294.2M | $385.8M | $2.94B | $238.4M | $466.7M | $139.9M | $372.9M | $273.9M |
| EPS, basic | 1.88 | 1.97 | 1.49 | 1.95 | 59.80 | 4.85 | 9.44 | 2.85 | 7.63 | 5.65 |
| EPS, diluted | 1.87 | 1.96 | 1.48 | 1.94 | 59.16 | 4.81 | 9.33 | 2.81 | 7.52 | 5.59 |
| Shares, diluted (wtd. avg.) | $200.0M | $200.4M | $199.3M | $198.8M | $49.8M | $49.6M | $50.0M | $49.7M | $49.6M | $49.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $110.6M | $107.6M | $120.8M | $138.6M | $96.6M | $116.8M | $89.5M | $80.2M | $88.8M | $100.8M |
| Receivables | $829.0M | $717.0M | $609.7M | $557.8M | $515.3M | $435.4M | $435.3M | $374.7M | $316.6M | $291.4M |
| Inventory | $846.0M | $802.7M | $735.6M | $628.7M | $585.6M | $570.4M | $506.9M | $468.8M | $454.1M | $417.7M |
| Total current assets | $2.11B | $1.95B | $1.70B | $1.53B | $1.47B | $1.27B | $1.16B | $1.09B | $953.2M | $937.1M |
| Property, plant and equipment | $2.08B | $1.86B | $1.63B | $1.41B | $1.35B | $1.28B | $1.13B | $976.0M | $910.1M | $877.7M |
| Goodwill | $3.85B | $3.84B | $3.62B | $3.61B | $2.57B | $2.45B | $2.43B | $2.39B | $2.35B | $2.16B |
| Other intangibles | $1.59B | $1.79B | $1.71B | $1.89B | $1.27B | $1.29B | $1.41B | $1.52B | $504.7M | $441.1M |
| Total assets | $12.39B | $12.32B | $11.66B | $11.49B | $9.61B | $6.74B | $6.27B | $6.11B | $4.86B | $4.48B |
| Accounts payable | $300.4M | $260.5M | $261.9M | $248.8M | $161.4M | $176.0M | $150.1M | $146.4M | $142.1M | $107.4M |
| Short-term debt | $47.8M | $33.3M | $45.4M | $412.6M | $83.4M | $409.3M | $563.7M | $37.1M | $23.4M | $210.7M |
| Total current liabilities | $1.11B | $1.02B | $969.0M | $1.28B | $732.1M | $1.00B | $1.11B | $536.5M | $396.1M | $543.2M |
| Long-term debt | $2.46B | $2.55B | $2.52B | $2.35B | $1.40B | $1.38B | $1.26B | $1.99B | $1.15B | $1.11B |
| Total liabilities | $4.16B | $4.23B | $4.11B | $4.32B | $2.66B | $2.91B | $2.65B | $2.81B | $1.68B | $1.78B |
| Retained earnings | $7.64B | $7.27B | $6.88B | $6.58B | $6.20B | $3.26B | $3.03B | $2.58B | $2.43B | $2.05B |
| Total equity | $8.24B | $8.08B | $7.55B | $7.17B | $6.94B | $3.82B | $3.63B | $3.31B | $3.18B | $2.70B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $796.1M | $709.3M | $607.5M | $692.4M | $738.6M | $486.6M | $713.2M | $668.9M | $593.6M | $509.6M |
| Depreciation and amortisation | $377.4M | $375.1M | $367.7M | $346.1M | $309.3M | $149.9M | $135.0M | $128.4M | $188.4M | $198.3M |
| Stock-based compensation | $70.5M | $75.1M | $62.1M | $54.2M | $43.8M | $37.6M | $35.1M | $43.2M | $37.2M | $29.9M |
| Capital expenditure | $362.4M | $421.2M | $392.5M | $242.0M | $214.4M | $310.4M | $292.1M | $193.6M | $127.2M | $152.6M |
| Investing cash flow | -$372.9M | -$764.6M | -$449.0M | -$1.83B | -$450.3M | -$364.5M | -$351.3M | -$1.52B | -$381.3M | -$418.7M |
| Financing cash flow | -$425.9M | $39.2M | -$173.9M | $1.19B | -$311.4M | -$95.5M | -$351.4M | $844.4M | -$227.9M | -$1.4M |
| Dividends paid | $0 | $0 | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $2.9M | $2.9M | $2.9M |
| Buybacks | $290.1M | $0 | $0 | $78.5M | $24.8M | $47.8M | $156.1M | $0 | $55.0M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-25-055615.
Others in SIC 3851
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| BLCO | Bausch & Lomb Corp | $6.44B | — | 6.5% |
| WRBY | Warby Parker Inc. | $3.02B | 2,435.0x | 13.0% |
| EYE | National Vision Holdings, Inc. | $1.32B | 45.2x | 9.0% |
| STAA | STAAR SURGICAL CO | $1.18B | — | -23.7% |
| RXST | RxSight, Inc. | $265.2M | — | -3.9% |
| LUCYW | Innovative Eyewear Inc | $275.5K | — | 62.6% |
| ALC | ALCON INC | — | — | 4.9% |